levetiracetam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 185 Diseases   81 Trials   81 Trials   6476 News 


«12...1516171819202122232425...8182»
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma, Ospolot (sultiam) / AOP Orphan Pharma, Diacomit (stiripentol) / Biocodex, Meiji Seika
    Enrollment open, Trial completion date, Trial primary completion date:  EPIPOP: Population Pharmacokinetics of Antiepileptic in Pediatrics (clinicaltrials.gov) -  Jul 3, 2023   
    P=N/A,  N=1000, Recruiting, 
    Unknown status --> Recruiting | Trial completion date: Jun 2022 --> Jun 2026 | Trial primary completion date: Jun 2022 --> Jun 2026
  • ||||||||||  Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Journal:  Synergistic effects of vagus nerve stimulation and antiseizure medication. (Pubmed Central) -  Jun 27, 2023   
    Our data suggest that the combination of VNS with ASMs belonging to either SV2A modulators or slow sodium channel inhibitors could be optimal to achieve a better seizure control following VNS. However, these preliminary data require further validation under controlled conditions.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Review, Journal:  Antiseizure Medication-Induced Alopecia: A Literature Review. (Pubmed Central) -  Jun 27, 2023   
    Alopecia should be considered one important adverse effect of ASMs. Patients reporting hair loss with ASM therapy should be further investigated, and specialist consultation is recommended.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma
    Journal:  Current treatment options for Familial Adult Myoclonus Epilepsy. (Pubmed Central) -  Jun 19, 2023   
    The ideal therapeutic option would be a precision treatment able to revert the genetic defect underlying it. Nevertheless, this does not seem to be an option available shortly.
  • ||||||||||  lamotrigine liquid oral suspension / OWP Pharma
    Journal:  Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. (Pubmed Central) -  Jun 14, 2023   
    Findings from this explorative study strengthen the evidence for the warning against the use of valproate in pregnancy and raise concern of risks of specific psychiatric disorders associated with topiramate and levetiracetam. This study provides reassuring evidence that lamotrigine, carbamazepine, and oxcarbazepine are not associated with long-term behavioral or developmental disorders but cannot rule out risks with higher doses.
  • ||||||||||  sodium valproate / Generic mfg., levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
    Journal, Monotherapy:  Change in Apo B100/A1 Ratio in Children With Epilepsy on Monotherapy With Sodium Valproate, Oxcarbazepine or Levetiracetam. (Pubmed Central) -  Jun 13, 2023   
    A prospective longitudinal study was conducted to assess the Apo B100/A1 ratio as a marker of cardiovascular risk in children with epilepsy aged 5-14 years on long-term anti-seizure medication monotherapy with either sodium valproate, oxcarbazepine, or levetiracetam. Apo B100/A1 ratio showed an increase after six months of monotherapy with oxcarbazepine (P=0.05).
  • ||||||||||  Journal:  Prescribing Trends of (Pubmed Central) -  Jun 7, 2023   
    VPAs use in WVWE during childbearing age continues, despite the high teratogenic risk, especially in women with bipolar disorder and headaches. Multidisciplinary care integrating family practice doctors, mental health, and neurology can prevent the enduring problem of teratogenesis in women taking ASM.
  • ||||||||||  levetiracetam / Generic mfg.
    Retrospective data, Review, Journal:  A comprehensive narrative review of epilepsy with eyelid myoclonia. (Pubmed Central) -  Jun 5, 2023   
    Broad-spectrum antiseizure medications such as valproate, levetiracetam, lamotrigine, and benzodiazepines are typically used. Seizures typically persist into adulthood, and drug-resistant epilepsy is reported in over 50%.
  • ||||||||||  levetiracetam / Generic mfg.
    Journal:  Use of (Pubmed Central) -  May 31, 2023   
    Levetiracetam appears to be a safe and effective medication for PTS prophylaxis in combat casualties. The rate of PTSs in combat-related TBI on appropriate prophylaxis is low.
  • ||||||||||  Epilepsy and Multiple Sclerosis - a Clinical Conundrum (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_892;    
    It is now known that epilepsy and MS can accumulate lesions in both the gray and white matter, and in the context of MS seizures can exacerbate demyelination; our records show an aggressive burden of disease, onset < 12 years notwithstanding. Hence, MS lesions can become epileptogenic and require treatment.
  • ||||||||||  Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance
    SLC35A2-CDG related early onset epileptic encephalopathy: Clinical features and treatment of epilepsy (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_767;    
    Moreover, increased frequency of epileptic seizures was observed probably due to reduction in serum ketone levels. Although seizure control was partially achieved (>50%) with the ketogenic diet, she did not benefit from oral galactose supplementation, which can be considered as a precision medicine for SLC35A2-CDG in the literature.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma
    Seizures in CLN2 patients receiving enzyme replacement therapy (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_757;    
    Most patients were treated with 2 AEDs, most common being VPA with CLB. EEG deterioration was found in two patients.
  • ||||||||||  clonazepam / Generic mfg., levetiracetam / Generic mfg.
    TRAPPC4-related neurodevelopmental disorder: a recent TRAPPopathy (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_721;    
    TRAPPC4-related neurodevelopmental disorder is a recent TRAPPopathy that should be considered in children with microcephaly associated with neurodegenerative disease. With this report we intend to draw attention to the emergence of new diagnoses of neurogenetic diseases and the importance of genome re-analysis.
  • ||||||||||  Enterovirus infection of the central nervous system in five neonates (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_546;    
    Diagnosis leads to earlier discontinuation of antibiotic treatment and shorter hospital stay. Neonates with EV infection should be screened for cardiac complications and in severe cases treated with IVIG.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Successful Use of Pulse IV Methylprednisolone in Epileptic Encephalopathy (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_514;    
    Pulse IV methylprednisolone is potentially a good and safe treatment option for children with EE, especially if considered early in their management. Further studies are needed to characterise the exact group of children this will benefit.
  • ||||||||||  Report of life threatening ictal apnoeas responsive to Ketogenic Diet (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_511;    
    Ketogenic diet was effective in this patient and despite she does not remain seizure free, the features of the seizures have changed being now safe for the patient being out of hospital. The ketogenic diet should be considered earlier as treatment in patients with these type of seizures.
  • ||||||||||  lacosamide / Generic mfg., levetiracetam / Generic mfg., clobazam / Generic mfg.
    Long-term effect of early ketogenic diet on PNKP mutation-associated epileptic encephalopathy (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_507;    
    The good response to the ketogenic diet marked a before and after in the clinical evolution of this patient. Probably, the early establishment of the ketogenic diet in this and other genetic syndromes that occur with refractory epilepsy can help to better control seizures, even partially improve their psychomotor development.
  • ||||||||||  levetiracetam / Generic mfg.
    Lamotrigine effectiveness for eyelid myoclonia. (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_506;    
    Probably, the early establishment of the ketogenic diet in this and other genetic syndromes that occur with refractory epilepsy can help to better control seizures, even partially improve their psychomotor development. Lamotrigine is an effective drug option in cases of eyelid myoclonia.
  • ||||||||||  Kineret (anakinra) / SOBI
    Febrile infection-related epilepsy syndrome - case report (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_498;    
    A ketogenic diet and various antiepileptic drugs (levetiracetam, clobazam, lacosamide, topiramate, phenobarbital) were introduced... FIRES is rare but diagnostically and therapeutically challenging disorder which must be considered in the differential diagnosis of refractory status epilepticus.
  • ||||||||||  levetiracetam / Generic mfg., carbamazepine / Generic mfg.
    The Effects of Antiepileptic Drugs on heart rate, QT interval, TpE interval and Tpe-QTc ratio in children with epilepsy (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_470;    
    Although many studies are conducted on the ECG changes and underlying cardiac electrophysiological changes observed in pediatric epilepsy, their clinical significance is still not fully known. Our study will be important in terms of clinical use of these markers in the evaluation of arrhytmia tendency in childhood, and also in terms of raising awareness about cardiovascular system (CVS) comorbidities in the follow-up of pediatric patients with epilepsy.
  • ||||||||||  levetiracetam / Generic mfg.
    Temporal encephalocele associated epilepsy in a patient with tectal glioma: a case report (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_469;    
    Seizures are infrequent with tectal glioma, with 12% incidence reported in a series of 66 pediatric patients (Epilepsia, 56(9):e139-e142, 2015). No temporal encephalocele was reported amongst these or in any other reported patients with tectal glioma.
  • ||||||||||  Novel GRIN2D Variation in a baby with Epileptic Encephalopathy and Response to NMDA Receptor Channel Blocker-a Case Report (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_464;    
    She was started on sodium valproate, clobazam, phenobarbitone, lamotrigione and levetiracetam sequentially which failed to achieve seizure control...Adjunctive therapy with memantine and prednisolone showed marked clinical improvement...It demonstrates the importance of early genetic testing and functional evaluation of mutations. It also highlights the potential for individualized treatment guided by molecular genetics.
  • ||||||||||  phenobarbital / Generic mfg., levetiracetam / Generic mfg.
    Genotype-Phenotype Correlation and Variability in MEF2C Gene Mutations (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_460;    
    This study brings additional data on the phenotype of MEF2C-related disorders and documents the severity of this condition, which can aid healthcare providers in diagnosing patients and delivering the best care possible to children and their families. The small number of cases introduces a bias in the interpretation of clinical-genetic correlation.
  • ||||||||||  rufinamide / Generic mfg., levetiracetam / Generic mfg., clobazam / Generic mfg.
    Etiological approach to Lennox-Gastaut syndrome and its impact on prognosis: A single-center experience (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_455;    
    In the literature, the etiology of 25-35% of the patients is unknown and it is thought that there is probably a genetic cause and/or predisposition in these patients. Therefore, studies about on pathogenesis and genetic origin of LGS are needed to improve the treatment.
  • ||||||||||  acetazolamide / Generic mfg.
    Acetazolamide - an old but the first precision drug for CHD2-related epilepsy? (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_440;    
    ACZ, a carbonic anhydrase inhibitor, reduces the excitability of cortical neurons and suppresses neural discharges in the Maximal Electroshock model. It has been approved for the treatment of epilepsy since 1953, but has been inadequately studied by current standards and its use has been limited.